MktsMarkets

INmune Bio Inc.
NASDAQ: INMBKey statistics
INMB News
Stories mentioning INMB from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 50.00 | |||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | ||||||||
| Research & Development | 3,641 | 2,329 | 4,887 | 5,804 | 7,639 | 7,353 | 10,067 | 7,053 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 5,812 | 5,474 | 7,433 | 24,571 | 9,955 | 9,467 | 12,286 | 9,865 |
| Operating Income (Loss) | (5,812) | (5,474) | (7,433) | (24,571) | (9,905) | (9,467) | (12,286) | (9,865) |
| Interest Income | ||||||||
| Interest Expense | 0.00 | 37.00 | 145.00 | 250.00 | ||||
| Other Expense | 166.00 | |||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (5,407) | (5,264) | (6,472) | (24,458) | (9,739) | (9,218) | (12,093) | (9,746) |
| Earnings Per Share (Basic) | (0.20) | (0.21) | (0.24) | (1.05) | (0.43) | (0.46) | (0.60) | (0.50) |
| Earnings Per Share (Diluted) | (0.20) | (0.21) | (0.24) | (1.05) | (0.43) | (0.46) | (0.60) | (0.50) |
| Weighted Average Shares Outstanding (Basic) | 26,585 | 24,758 | 26,585 | 23,298 | 22,496 | 19,944 | 20,186 | 19,307 |
| Weighted Average Shares Outstanding (Diluted) | 26,585 | 24,758 | 26,585 | 23,298 | 22,496 | 19,944 | 20,186 | 19,307 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About INMB
INmune Bio Inc. (NASDAQ: INMB) is a stock listed on the Nasdaq Stock Market under the ticker symbol INMB. It last traded at $0.8900 (Nov 19, 2026, 4:00 PM ET), down 13.2% on the day. That gives INmune Bio a market capitalisation of $31.9M.
Over the past 52 weeks INMB has traded between $0.8900 and $2.60.
For the quarter ended Mar 31, 2026 it reported a net loss of $5.4M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$5.4M |
| Dec 31, 2025 | — | -$5.3M |
| Sep 30, 2025 | — | -$6.5M |
| Jun 30, 2025 | — | -$24.5M |
From INmune Bio’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…